icon-folder.gif   Conference Reports for NATAP  
 
  ICAAC
48th Annual ICAAC / IDSA 46th Annual Meeting
October 25-28, 2008
Washington, DC
Back grey_arrow_rt.gif
 
 
 
RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients
 
 
  Reported by Jules Levin, ICAAC/IDSA 25-28 October 2008 Washington, DC
 
G. Moyle, M. Boffito, Z. Shen, K. Manhard, B. Sheedy, V. Hingorani, M. Nguyen, T. Nguyen, B. Quart, L. Yeh, V. Ong
 
RDEA806 AUTHOR CONCLUSIONS
 
--Well tolerated with robust antiviral effect across all doses
--Tmax ranged from 2-6 hours, half-life ~9-12 hours
--Antiviral activity similar between 800 mg QD and 400 mg BID
--No significant induction of CYP3A4, indicating a low potential for drug interactions
--Significant reduction in uric acid across all doses, with no effect on the renal excretion of tenofovir.
--Phase 2b in antiretroviral treatment-na´ves planned to begin this quarter
 
Preclinical Background
--RDEA806 is a potent (EC50wt= 3 nM), selective HIV NNRTI designed to maintain activity against the most common mutations observed with efavirenz (EC50K103N= 2.3 nM)
--High barrier to resistance
--Cytotoxicity selectivity index > 9,000
--Highly protein bound (~99.5%)
--Limited metabolism by CYP450 (none by 2B6) and no inhibition or induction of CYP450
--Completed animal reproduction studies have shown no evidence of teratogenicity or impairment of fertility
--Highly water soluble, allowing for preparation of easy to swallow tablets easy to swallow tablets

sample-1.gif

prof-2.gif

load-3.gif

folrmax-4.gif

cohort-5.gif

cyp-6.gif

acrid-7.gif

teno-8.gif